explore -WSS

explore

author：Wikipedia 2025-09-27 13:03:55 - browse：18

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Eli Lilly’s Zepbound improved liver scarring in mid

hotspot

leisure time

WSS

The UK government moves asylum

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

The most pressing bird flu mysteries scientists want answered

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

Boeing's 1st astronaut flight bumped into next year, more repairs needed

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

focus

explore

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

BD to buy Edwards patient monitoring unit for $4.2 billion

BioMarin wins approval for gene therapy to treat hemophilia A

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

ChatGPT in medicine: STAT answers readers' burning questions

Data don't support strong claims for Covid

Walensky prepares to leave CDC — and Congress — behind

Why workplace violence is so common in health care

Supreme Court strikes down use of affirmative action

Democratic lawmaker calls for 'well

focus

The UK government moves asylum

Elevance PBM president out as customers face prescription chaos

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Moderna hits safety problems in bold bid to reinvent medicine

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

Medicare Advantage's lean provider networks lead CMS complaints

hotspot

leisure time

focus

explore